Assisting clients select and close a wide range of debt facilities that support discovery and development activities, clinical trials, pre-commercial launches, equipment purchases, and working capital needs.
Assisting clients identify and complete discrete projects that align with key corporate initiatives, including capital planning, financial modeling and analysis, treasury management, and debt restructurings.
Synthases are molecules that catalyze chemical reactions critical for the health and vitality of all living organisms.
Synthase Capital Partners fosters relationships between capital seekers and providers, serving as a catalyst in securing the necessary funds to fuel innovation.
We know and understand the innovation economy.
We exclusively collaborate with venture-backed private and public life science companies, and maintain strong relationships with capital providers who cater to the distinctive requirements of innovative, high-growth companies operating on the frontier.
We align our work and priorities to your strategic goals.
Our "north star" is to support and enable your tactical objectives, whether that involves raising capital, sourcing collaboration partners, or pursuing a range of other strategic objectives.
Founder and Managing Director
Derek has nearly two decades of experience supporting the capital needs of innovative technology and life science companies and has originated, structured, and managed over $700 million in debt capital commitments. Prior to founding Synthase Capital Partners, Derek was an Executive Director at J.P. Morgan and Managing Director at Silicon Valley Bank. Derek is a graduate of the University of Vermont and lives in San Diego, California with his wife and three children.
858 204-6864
Follow us